公开(公告)号：US12213984B2

公开(公告)日：2025-02-04

申请号：US17521335

申请日：2021-11-08

Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

Inventor： Yoshinori Fukui ,  Takehito Uruno ,  Yuki Sugiura

IPC: A61K31/575 ,  A61K31/7088 ,  A61K31/713 ,  A61K35/76 ,  A61K38/00 ,  A61K45/00 ,  A61K45/06 ,  A61K48/00 ,  A61P37/06 ,  C07K14/47

Abstract: An immunoregulatory agent containing a regulatory agent that regulates Dedicator of cytokinesis 2 (DOCK2)-mediated Rac activation as an active ingredient is provided.

公开(公告)号：US11213020B2

公开(公告)日：2022-01-04

申请号：US16079244

申请日：2017-02-24

Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

Inventor： Yoshinori Fukui ,  Kazuhiko Yamamura ,  Takehito Uruno ,  Masutaka Furue

IPC: A01K67/027 ,  G01N33/50 ,  C12Q1/66 ,  C12Q1/02 ,  A61K45/00 ,  C12N15/09 ,  C12N5/10 ,  G01N33/53 ,  C12Q1/68 ,  A61K49/00

Abstract: An atopic dermatitis model non-human animal, containing a gene mutation in which a complex containing dedicator of cytokinesis 8 (DOCK8) protein, mammalian STE20-like kinase 1 (MST1) protein, and endothelial PAS domain protein 1 (EPAS1) protein is not formed in CD4+ T cells.

公开(公告)号：US11311523B2

公开(公告)日：2022-04-26

申请号：US16517385

申请日：2019-07-19

Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

Inventor： Yoshinori Fukui ,  Takehito Uruno

IPC: A61K31/4412 ,  A61P35/04 ,  A61K45/00 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4453 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  G01N33/50 ,  A61P35/00 ,  G01N33/15

Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below wherein R5 in the group represented by Formula (3) is hydrogen.

公开(公告)号：US10406141B2

公开(公告)日：2019-09-10

申请号：US15553762

申请日：2016-02-26

Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

Inventor： Yoshinori Fukui ,  Takehito Uruno ,  Motomu Kanai ,  Shigeki Matsunaga ,  Takahiro Shirai ,  Shigeyuki Yokoyama ,  Teruki Honma ,  Mutsuko Niino ,  Daisuke Takaya

IPC: A61K31/55 ,  A61K45/00 ,  A61P35/00 ,  A61P35/04 ,  G01N33/15 ,  G01N33/50 ,  A61K31/444 ,  A61K31/541 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/4453 ,  A61K31/5377

Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below: wherein R5 in the group represented by Formula (3) is hydrogen.